Claims for Patent: 6,440,416

Summary for Patent: 6,440,416

Title:	Vaccines against cancer and infectious diseases
Abstract:	A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.
Inventor(s):	Goldenberg; David M. (Short Hills, NJ), Hansen; Hans J. (Westfield, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	08/183,381
Patent Claims:	1. A method of stimulating an immune response in a human against malignant cells or an infectious agent, which comprises the step of administering to said human an immunogenic amount of a baboon anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen that is a marker for a malignant cell or an infectious agent. 2. The method of claim 1, wherein said baboon anti-idiotype antibody or antibody fragment is an immunogenic functional mimic of an epitope on said antigen. 3. The method of claim 1, wherein said antigen is a marker for a malignant cell. 4. The method of claim 3, wherein said antigen is carcinoembryonic antigen. 5. The method of claim 4, wherein said baboon anti-idiotype antibody or antibody fragment acts as an immunogenic mimic of an epitope on carcinoembryonic antigen which is not shared with either nonspecific crossreacting antigen or meconium antigen. 6. The method of claim 1, wherein said antigen is a marker for a virus. 7. The method of claim 6, wherein said antigen is a human immunodeficiency virus envelope protein. 8. The method of claim 7, wherein said envelope protein is gp120. 9. The method of claim 1, wherein said antigen is a marker for an infectious microorganism selected from the group consisting of bacteria, rickettsia, mycoplasma, protozoa and fungi. 10. The method of claim 1, wherein said antigen is a marker for an infectious parasite. 11. The method of claim 1, wherein said baboon anti-idiotype antibody or antibody fragment is administered in combination with an immunostimulant adjuvant. 12. The method of claim 11, wherein said adjuvant is at least one member selected from the group consisting of Freund's adjuvant, alum, Bacillus Calmette-Guerin and tetanus toxoid. 13. The method of claim 1, further comprising the administration of said antigen. 14. The method of claim 1, wherein said human is a cancer patient suffering from a malignant solid tumor or hematopoietic neoplasm. 15. The method of claim 14, wherein said malignant solid tumor or hematopoietic neoplasm is a gastrointestinal, lung, breast, prostate, ovarian, testicular, brain or lymphatic lesion, a sarcoma or a melanoma lesion. 16. The method of claim 1, wherein said human is suffering from a viral infection. 17. The method of claim 1, wherein said human is suffering from infection by an infectious microorganism selected from the group consisting of bacteria, rickettsia, mycoplasma, protozoa and fungi. 18. The method of claim 1, wherein said human is suffering from infection by an infectious parasite. 19. The method of claim 1, wherein said human is not suffering from a malignancy or from an infection, and said immune response results in immunity against the development of malignancy by a cell having said malignant cell marker, or against infection by an infectious agent having said infectious agent marker. 20. An antitumor or antipathogen vaccine, comprising an immunogenic amount of a baboon anti-idiotype antibody or antibody fragment that is an immunogenic functional mimic of an antigen that is a marker for a malignant cell or infectious agent, and a physiologically acceptable vaccine vehicle. 21. The vaccine of claim 20, wherein said vehicle comprises an effective amount of an immunostimulant adjuvant. 22. The vaccine of claim 21, wherein said adjuvant is at least one member selected from the group consisting of Freund's adjuvant, alum, Bacillus Calmette-Guerin and tetanus toxoid. 23. The vaccine of claim 20, which further comprises said antigen. 24. The vaccine of claim 22, which further comprises said antigen. 25. The method of claim 1, wherein said antigen is carcinoembryonic antigen. 26. The method of claim 1, wherein said baboon anti-idiotype antibody or antibody fragment acts as an immunogenic mimic of an epitope on carcinoembryonic antigen which is not shared with either nonspecific cross-reacting antigen or meconium antigen.

Details for Patent 6,440,416

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2019-08-27